TNFSF8 (PRA-052 Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA023996MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
MK8690 research-grade biosimilar; MK-8690 research-grade biosimilar; PR600 research-grade biosimilar; PR-600 research-grade biosimilar; PRA052 research-grade biosimilar ;TNFSF8 antibody; CD30L antibody; CD30LG antibody; Tumor necrosis factor ligand superfamily member 8 antibody; CD30 ligand antibody; CD30-L antibody; CD antigen CD153 antibody
Species Reactivity
Human
Immunogen
Recombinant Human TNFSF8 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to PRA-052, targeting TNFSF8 (tumor necrosis factor superfamily member 8), also known as CD30 ligand or CD153. TNFSF8 is a type II transmembrane glycoprotein primarily expressed on activated T cells, macrophages, and certain dendritic cells. It binds to CD30 (TNFRSF8) and plays critical roles in immune regulation, including T cell activation, cytokine production, and inflammatory responses. TNFSF8/CD30 interactions are particularly significant in the pathogenesis of lymphoproliferative disorders, Hodgkin lymphoma, and anaplastic large cell lymphoma, where aberrant CD30 signaling contributes to malignant transformation and disease progression. This pathway is also implicated in autoimmune conditions and transplant rejection.

As a biosimilar to the reference antibody PRA-052, this product provides researchers with a reliable tool for investigating TNFSF8 biology, CD30-CD30L signaling mechanisms, and their roles in immune-mediated diseases and hematologic malignancies. It supports studies exploring therapeutic targeting strategies and biomarker development in oncology and immunology research.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells.
Gene References into Functions
  1. circulant sCD30L is functionally active and that it may favor persistence of active inflammation by inducing apoptosis of CD30(+)T cells, known to down-modulate inflammation in rheumatoid synovitis. PMID: 24447865
  2. TNFSF8 is an important leprosy T1R susceptibility gene. PMID: 25320285
  3. The heritability of IgA levels is moderate and can partly be attributable to common variation in the CD30L locus. PMID: 24676358
  4. The TNFSF8 polymorphisms rs927374 and rs2295800 were associated with neutrophil count. This finding suggests that post-MI inflammatory response is genetically modulated. PMID: 22033252
  5. Positional candidate gene screening in the SPA2 locus allowed us to identify and replicate an association between a rare SNP located in TNFSF8 and spondylarthritis. PMID: 21480186
  6. a possible role of novel TNFSF8 variants in susceptibility to lung cancer. PMID: 21292647
  7. capability to up-regulate expression of CD30, release of soluble CD30 and production of IL-4 in pre-activated T cells upon co-culture PMID: 11728464
  8. Mast cells were found to be the predominant CD30 ligand-positive (CD30L-positive) cell in the chronic inflammatory skin diseases psoriasis and atopic dermatitis. PMID: 16964309
  9. CD153 antigen was expressed by synovial mast cells, and correlated with serum levels, in Rheumatoid Arthritis patients PMID: 19208589
  10. Single nucleotide polymorphism in TNFSF8 gene is associated with bone disease in myeloma. PMID: 19657367

Show More

Hide All

Subcellular Location
Membrane; Single-pass type II membrane protein.
Protein Families
Tumor necrosis factor family
Database Links

HGNC: 11938

OMIM: 603875

KEGG: hsa:944

STRING: 9606.ENSP00000223795

UniGene: Hs.494901

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*